Related Experiment Video
Updated: Jun 23, 2026
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review
Juncong Fan1, Yeqin Ni2, Rong Ni1
1The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People's Hospital, Hangzhou, Zhejiang, 310053, China.
Opinion Statement:
Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by rapid progression, restricted therapeutic options, and dismal prognosis. Conventional therapeutic modalities demonstrate limited efficacy, especially for unresectable or metastatic cases. Recent advancements in molecular profiling have revolutionized ATC management, facilitating the development of novel targeted therapies, immunotherapies, and multimodal regimens. Growing clinical evidence indicates these innovative approaches may enhance locoregional control, increase surgical candidacy in select patients, and extend overall survival. Incorporating molecular-guided therapies into multidisciplinary care is fundamentally transforming ATC management. Nevertheless, therapeutic resistance, intratumoral heterogeneity, and the paucity of large-scale prospective trials remain major obstacles. Future efforts should focus on optimizing combinatorial strategies and developing robust biomarker-driven algorithms to improve clinical outcomes in ATC.
Insights
Anaplastic thyroid carcinoma (ATC) is aggressive with poor outcomes. Molecular-guided therapies offer new hope by improving treatment efficacy and survival rates for patients with this challenging cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive thyroid cancer.
- Current treatments for ATC have limited efficacy, leading to poor patient prognosis.
- Molecular profiling has opened new avenues for understanding and treating ATC.
Purpose of the Study:
- To review the impact of recent advancements in molecular profiling on anaplastic thyroid carcinoma management.
- To highlight the potential of novel targeted therapies and immunotherapies in improving patient outcomes.
- To discuss the challenges and future directions in optimizing ATC treatment strategies.
Main Methods:
- Review of current literature on anaplastic thyroid carcinoma.
- Analysis of recent clinical evidence regarding molecular-guided therapies.
- Discussion of therapeutic resistance and intratumoral heterogeneity.
Main Results:
- Molecular profiling has led to the development of targeted therapies and immunotherapies for ATC.
- Innovative approaches show promise in enhancing locoregional control and extending survival.
- Multidisciplinary care incorporating molecular-guided therapies is transforming ATC management.
Conclusions:
- Targeted therapies and immunotherapies represent a significant advancement in ATC treatment.
- Overcoming therapeutic resistance and intratumoral heterogeneity is crucial for future progress.
- Biomarker-driven algorithms and combinatorial strategies are essential for improving clinical outcomes in ATC.
